{
    "clinical_study": {
        "@rank": "131257", 
        "arm_group": {
            "arm_group_label": "Aripiprazole", 
            "arm_group_type": "Experimental", 
            "description": "Dose level: 2, 5, 10, 15 mg/day\nStarting dose: 2 mg/day\nDose increment: The dose should be gradually increased according to the investigator's judgment of subject's response.\nTarget dose: 5-15 mg/day\nMaximum dose: 15 mg/day\nFlexibly dosed (2 to 15 mg/day) aripiprazole (oral tablet or solution) is taken once in a day at the same time without regarding to meals"
        }, 
        "brief_summary": {
            "textblock": "-  To evaluate the efficacy of flexibly dosed aripiprazole in reducing serious behavioral\n           problems in Asian children and adolescents with a diagnosis of autism  spectrum\n           disorder, as measured by change from baseline to endpoint on the irritability subscale\n           of the aberrant behavior checklist (ABC-I).\n\n        -  To evaluate the long-term safety and tolerability of flexibly dosed aripiprazole in the\n           treatment of serious behavioral problems in Asian children and adolescents with a\n           diagnosis of autism spectrum disorder."
        }, 
        "brief_title": "Study to Evaluate the Efficacy and Safety of Aripiprazole", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Autism", 
        "condition_browse": {
            "mesh_term": [
                "Autistic Disorder", 
                "Child Development Disorders, Pervasive"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. Study design\n\n      - Multi-national, Multi-center, 52 weeks open label, single arm design"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  6 to 17 years of age.\n\n          -  Meeting the diagnostic criteria for autistic disorder specified by the Diagnostic and\n             Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR),\n             with a diagnosis corroborated by the  Autism Diagnostic Interview-Revised (ADI-R)\n             diagnostic instrument and demonstrated behaviors such as tantrums, aggression,\n             self-injurious behavior, or a combination of these.\n\n          -  Clinical Global Impressions (CGI) Severity subscale score \u2265 4 at screening and\n             baseline.\n\n          -  Aberrant Behavior Checklist (ABC) Irritability subscale score \u226518 at screening and\n             baseline.\n\n          -  Mental age \u2265 18 months.\n\n          -  Women of childbearing potential (WOCBP) have to use an adequate method of\n             contraception\n\n          -  WOCBP must have had a negative serum or urine pregnancy test.\n\n          -  The patient and/or the designated guardian(s) or caregiver(s) who are able to\n             comprehend and comply with the protocol requirements, in the opinion of the\n             investigator and have consented to participate by signing an informed consent form.\n\n        Exclusion Criteria:\n\n          -  Current diagnosis of bipolar disorder, schizophrenia, major depressive disorder,\n             Rett's disorder, or Fragile-X syndrome.\n\n          -  History of neuroleptic malignant syndrome.\n\n          -  Significant risk of committing suicide based on history or routine psychiatric status\n             examination.\n\n          -  History of seizure in the past 1 year.\n\n          -  History of severe head trauma or stroke\n\n          -  History or current evidence of any unstable medical conditions\n\n          -  Patient considered treatment resistant to neuroleptic medication\n\n          -  Patient considered treatment resistant to aripiprazole\n\n          -  Woman who is pregnant or breastfeeding\n\n          -  ECG: QTc  >  475 msec\n\n          -  Platelets \u2264  75,000/\u03bcL\n\n          -  Hemoglobin \u2264 9 g/dL\n\n          -  Neutrophils  \u2264  1.0x10^3/\u03bcL\n\n          -  Aspartate or alanine transaminase (AST or ALT) > 3xULN\n\n          -  Serum creatinine  \u2265 2 mg/dL\n\n          -  Patient weighed < 15 kg\n\n          -  Patient who participated in any other clinical trial within 4 weeks\n\n          -  Patient determined to require the administration of the prohibited medications during\n             the study period\n\n          -  Patient with other conditions determined by the investigator to be inappropriate for\n             this clinical study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "79", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02069977", 
            "org_study_id": "031OTC1301"
        }, 
        "intervention": {
            "arm_group_label": "Aripiprazole", 
            "intervention_name": "Aripiprazole", 
            "intervention_type": "Drug", 
            "other_name": "Abilify\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "Aripiprazole"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Autism", 
            "Aripiprazole", 
            "Abilify"
        ], 
        "lastchanged_date": "March 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ilsan", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "411-706"
                    }, 
                    "name": "Inje University Ilsan Paik Hospital"
                }, 
                "investigator": {
                    "last_name": "Eun-Jin Park, MD, PhD.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-710"
                    }, 
                    "name": "Samsung Medical Center"
                }, 
                "investigator": {
                    "last_name": "Yoo-Sook Joung, MD., PhD.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "138-736"
                    }, 
                    "name": "Asan Medical Center"
                }, 
                "investigator": {
                    "last_name": "Hyo-Won Kim, MD,PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pasig", 
                        "country": "Philippines"
                    }, 
                    "name": "Medical City"
                }, 
                "investigator": {
                    "last_name": "Stella Manalo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quezon City", 
                        "country": "Philippines"
                    }, 
                    "name": "Philippine Children's Medical Center"
                }, 
                "investigator": {
                    "last_name": "Alexis Reyes, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bangkok", 
                        "country": "Thailand", 
                        "zip": "10700"
                    }, 
                    "name": "Siriraj Hospital Mahidol University"
                }, 
                "investigator": {
                    "last_name": "Vitharon Boon-yasidhi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Korea, Republic of", 
                "Philippines", 
                "Thailand"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multinational, Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Aripiprazole in Asian Pediatric Patients With Autism Spectrum Disorder and Behavior Problems", 
        "other_outcome": {
            "description": "Safety will be evaluated based on below inormaiton.\nLaboratory test results (routine lab. and serum prolactin)\nVital signs (blood pressure, pulse, body temperature)\nECG\nWeight gain\nExtrapyramidal side effects (EPSEs) assessed by Simpson-Angus Rating Scale (SAS), Barnes Akathisia Rating Scale (BARS), and Abnormal Involuntary Movement Scale (AIMS)", 
            "measure": "Adverse events (AEs)", 
            "safety_issue": "Yes", 
            "time_frame": "Week 1, 2, 4, 8, 12, 24, 36, 52"
        }, 
        "overall_contact": {
            "email": "cheon.hyemi@cnrres.co.kr", 
            "last_name": "Hyemi Cheon", 
            "phone": "82-70-4033-3059"
        }, 
        "overall_official": {
            "affiliation": "Sumsung Medical Center", 
            "last_name": "Yoo-Sook Joung, MD. PhD.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Korea: Institutional Review Board", 
                "Thailand: Ethical Committee", 
                "Philippines: Ethics Committee", 
                "Philippines : Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Mean change from baseline to endpoint  of Part 1 (week 12)in the caregiver-rated ABC Irritability (ABC-I) subscale score.\nABC Scale will be completed by subject", 
            "measure": "irritability subscale of the aberrant behavior checklist", 
            "safety_issue": "No", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02069977"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Yoo-Sook Joung", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "ABC Scale will be completed by subject", 
                "measure": "Change from baseline in ABC-subscale of lethargy/social withdrawal, stereotypic behavior, hyperactivity, inappropriate speech", 
                "safety_issue": "No", 
                "time_frame": "Week 1, 2, 4, 8, 12, 24, 36, 52"
            }, 
            {
                "description": "CGI-S, CGI-I scale will be evaluated by investigator", 
                "measure": "Change of CGI-S, CGI-I from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 1, 2, 4, 8, 12, 24, 36, 52"
            }, 
            {
                "description": "Behavioral problems scale: Child Yale-Brown Obsessive-Compulsive Scale (CY-BOCS)", 
                "measure": "Change of Behavioral problems from baseline", 
                "safety_issue": "No", 
                "time_frame": "Week 12, 52"
            }, 
            {
                "description": "Adaptive Skills Scale: Vineland Adaptive Behavior Scale (VABS)", 
                "measure": "Change of Adaptive Skills from baseline", 
                "safety_issue": "No", 
                "time_frame": "week 12, 52"
            }, 
            {
                "description": "Parental stress scale: Parenting Stress Index (PSI)", 
                "measure": "Change of Parental stress from baseline", 
                "safety_issue": "No", 
                "time_frame": "Weekk 12, 52"
            }
        ], 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Korea Otsuka International Asia Arab", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Yoo-Sook Joung", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}